Treatments

According to the following articles, four structure classes can be identified for EGFR mutations. Exon 18 mutations belong among PACC mutations which are most sensitive to second-generation TKIs (afatinib, dacomitinib, poziotinib, neratinib..).

Classifying EGFR mutations by structure and function offers better way to match non-small cell lung cancer patients to treatments                                                                                                                             https://www.mdanderson.org/newsroom/classifying-egfr-mutations-by-structure-and-function.h00-159464001.html

https://www.ilcn.org/structure-based-classification-system-for-egfr-mutations-may-help-clinicians-personalize-treatments-for-more-patients/<br>

The articles are based on the following study:

Structure-based classification predicts drug response in EGFR-mutant NSCLC                              https://www.nature.com/articles/s41586-021-03898-1